Publications by authors named "N Latov"
Article Synopsis
- * Treatment typically involves rituximab, a B-cell depleting agent, although there are currently no FDA-approved therapies for this condition, and past trials have not met their desired outcomes.
- * A case study showed two patients had a significant reduction in anti-MAG antibodies after extended rituximab treatments, suggesting that prolonged therapy may be necessary for effective management of the disease.
Background: Patients with anti-MAG neuropathy present with distal demyelinating polyneuropathy, IgM monoclonal gammopathy, and elevated titers of anti-MAG antibodies.
Objective: This paper reviews what is known about the clinical presentation, course, pathophysiology, and treatment of anti-MAG neuropathy, with considerations for the design of therapeutic trials.
Methods: A literature review of the medical and scientific literature related to anti-MAG neuropathy, and the design of therapeutic clinical trials in peripheral neuropathy.
Article Synopsis
- The ADVANCE-CIDP 1 study tested the effectiveness and safety of facilitated subcutaneous immunoglobulin (fSCIG) in reducing relapses of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) compared to a placebo.
- The study was a phase 3 trial that involved 132 eligible adults who had been receiving stable intravenous immunoglobulin (IVIG) prior to being randomized to either fSCIG or placebo for 6 months.
- Results showed that fSCIG significantly reduced CIDP relapse rates compared to the placebo, although adverse events were more frequent with fSCIG, but serious complications were less common.
Correction: Latov, N. Infection, Anti-Ganglioside Antibodies, and Neuropathy. 2022, , 2139.
Microorganisms
March 2023
The authors wish to make the following corrections to this paper [...
View Article and Find Full Text PDFIntroduction: Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an autoimmune peripheral nerve disorder that is characterized by subacute onset, progressive or relapsing weakness, and sensory deficits. Proven treatments include intravenous immunoglobulin (IVIg), corticosteroids, and plasma exchange. This review focuses on the mechanisms of action, pharmacodynamics, genetic variations, and disease characteristics that can affect the efficacy of IVIg.
View Article and Find Full Text PDF